PBLS financial statements
The full income statement, balance sheet, and cash-flow statement for Parabilis Medicines Inc. (PBLS), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
| Line item | Trend | Q2 2026 |
|---|---|---|
| Income Statement | as ofJun 30 ’26 | |
| Revenue | 148K | |
| 51.0M | ||
| Research & development | 39.4M | |
| Selling, general & administrative | 11.7M | |
| General & administrative | 11.7M | |
| Operating income | -50.9M | |
| Interest expense | 210K | |
| Other non-operating income | -1.58M | |
| -52.5M | ||
| Net income to common | -67.0M | |
| -$2.32 | ||
| EPS (basic) | -$2.32 | |
| Weighted-avg shares (basic) | 28.9M | |
| Weighted-avg shares (diluted) | 28.9M | |
| Balance Sheet | as ofJun 30 ’26 | |
| 1.13B | ||
| Cash & equivalents | 1.09B | |
| Short-term investments | 33.6M | |
| Prepaid expenses | 4.70M | |
| 1.18B | ||
| Property, plant & equipment | 6.72M | |
| Operating lease right-of-use | 36.0M | |
| 62.8M | ||
| Accounts payable | 18.5M | |
| Accrued liabilities | 20.0M | |
| Deferred revenue | 10.4M | |
| Short-term & current debt | 5.71M | |
| Current lease liability | 7.59M | |
| Finance lease liability (current) | 669K | |
| 128M | ||
| Long-term debt | 700K | |
| Deferred revenue (non-current) | 31.1M | |
| Non-current lease liability | 32.4M | |
| Finance lease liability | 1.13M | |
| 1.05B | ||
| Preferred stock | 0.00 | |
| Common stock | 12.0K | |
| Additional paid-in capital | 1.69B | |
| Retained earnings | -639M | |
| Accumulated other comprehensive income | -18.0K | |
| Total liabilities & equity | 1.18B | |
| Common shares issued | 122M | |
| Common shares outstanding | 122M | |
| Cash Flow | as ofJun 30 ’26 | |
| Depreciation & amortization | 600K | |
| Valuation Ratios | as ofJun 30 ’26 | |
| Market cap | 3.34B | |
| P/B | 3.2× | |
| Source filing | 10-Q |
About this data
Source: PBLS’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all PBLS filings on SEC EDGAR → Not investment advice.